The company associated with the drug Lucentis is Genentech [1]. Genentech developed Lucentis, a medication used to treat conditions affecting the eye, such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV) [1][2].
How is Lucentis made available to patients?
Lucentis is administered as an intravitreal injection, meaning it is injected directly into the vitreous humor of the eye [2]. This method of delivery is overseen by a healthcare professional [2].
What is the scientific name of Lucentis?
The active ingredient in Lucentis is ranibizumab [2]. Ranibizumab is a monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A) [2][3]. By blocking VEGF-A, it helps to reduce abnormal blood vessel growth and leakage in the eye [2][3].
When does Lucentis's patent protection end?
Patent information for Lucentis can be complex and may involve multiple patents with varying expiry dates. For detailed and up-to-date information on Lucentis patent expiries, consulting a resource like DrugPatentWatch.com is recommended [4].
Who are Lucentis's main competitors?
Other medications that target VEGF-A for similar eye conditions are considered competitors to Lucentis. These include Eylea (aflibercept) and Avastin (bevacizumab) [3]. Eylea is also an intravitreal injection, while Avastin, originally developed for cancer treatment, is sometimes used off-label for eye conditions [3].
What are the clinical uses for Lucentis?
Lucentis is primarily prescribed for the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults [1][2]. It is also used for diabetic macular edema (DME), a complication of diabetes that can impair vision, and for myopic choroidal neovascularization (mCNV), a condition characterized by abnormal blood vessel growth in the eye associated with high myopia [1][2].
Where can I find more information on drug patents like Lucentis'?
For comprehensive and detailed information on drug patents, including expiry dates, patent challenges, and related intellectual property for medications like Lucentis, DrugPatentWatch.com is a valuable resource [4].
What are the potential risks or side effects of Lucentis?
As with any medication, Lucentis carries potential risks and side effects. Common side effects reported include eye inflammation, pain, or discomfort following the injection, and an increased risk of retinal detachment or other eye-related issues [2]. Serious side effects, though less common, can occur [2].
Can generic or biosimilar versions of Lucentis be developed?
The development of generic or biosimilar versions of drugs like Lucentis is contingent on patent expiry and regulatory approval processes. Ranibizumab is a biologic, so biosimilar development pathways apply [4]. Once relevant patents expire and regulatory hurdles are cleared, biosimilar versions could become available [4].
What is the mechanism of action for ranibizumab?
Ranibizumab is a humanized IgG1 kappa isotype antibody fragment that binds to and inhibits all active forms of VEGF-A [2][3]. VEGF-A is a key mediator of angiogenesis (the formation of new blood vessels) and vascular permeability [2][3]. In conditions like wet AMD, excessive VEGF-A leads to the growth of abnormal, leaky blood vessels in the retina, causing vision loss [2][3]. By inhibiting VEGF-A, ranibizumab reduces this abnormal vascularization and leakage, helping to preserve or improve vision [2][3].
Sources:
[1] https://www.gene.com/medicines/retina/lucentis
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/lucentis-ranibizumab-injection-information
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797971/
[4] https://drugpatentwatch.com/